The Earle A. Chiles Research Institute (EACRI) is a unique part of the fabric of Providence. Founded in 1988, EACRI is dedicated to bench to bedside investigation in the fields of cardiovascular diseases, infectious diseases and oncology. The EACRI occupies the top floor of a major patient care tower of PPMC.
Oncology research is a major activity. As summarized in the following table, as of 6/1/05, the Franz Cancer Research Center, within the Earle A. Chiles Research Institute has active research awards totaling nearly $10,000,000. Note that all grants listed are the result of peer-reviewed competitive grants from the NH, Department of Defense (DOD), and American Cancer Society.
Earle A. Chiles Research Institute – Franz Cancer Research Center Grant Summary
PI/Project Name
Agency
Dates of Award
Total Award
Brendan Curti/Clinical Development of Anti-OX40 & OX40L
NIH
7/1/04 – 6/30/09
$1,458,575
Bernard Fox/Development of Effective Immunotherapy for Prostate Cancer Pts
DOD
4/1/03 – 3/31/06
$533,625
Bernard Fox/Identify & Amplify T Cell Effector Mechanisms
NIH
7/1/01 – 6/30/05
$1,062,980
Bernard Fox/Mechanisms that Regulate Tumor Specific Immune Response
NIH
8/1/03 – 7/31/08
$1,337,620
Hong-Ming Hu/Novel Active Imm Strat for Lung + Bone Metastasis of Ca
ACS
7/1/03 – 6/30/07
$720,000
Hong-Ming Hu/TLR-Mediated DC Activation and Immune Reconstitution
NIH
4/1/04 – 3/31/09
$1,312,720
Walter Urba/gp10 Peptide Immunization After Lymphocyte Depletion
NIH
9/10/03 – 8/31/05
$633,236
Walter Urba/Peptide Booster Vaccination in A2+Melanoma Pts
NIH
4/1/04 – 3/31/06
$583,430
Andrew Weinberg/Enhancing Anti-Prostate Ca Immunity through OX40 Engagement
DOD
2/1/03 – 1/31/06
$533,625
Andrew Weinberg/Understand OX40 Mediated Tumor Immunotherapy
NIH
7/1/03 – 6/30/08
$1,583,090
Carl Ruby/Cancer Biology Training Grant through OHSU
NIH
10/1/03 – 9/30/05
$92,600
TOTALS
$9,851,501
As the project name indicates, the research is primarily laboratory-based.
However, Providence investigators are also very active in a large number of
pharmaceutical company-sponsored clinical trials.
The Infectious Diseases laboratory focuses on molecular diagnostic and evaluation of antimicrobials. The laboratory has 10 full-time employees with active participation of five MD consultants in Infectious Diseases.
At present, there are 19 active clinical trials in cardiovascular disease with a support staff of five and 10 clinical investigators.
